Another NASH setback as CymaBay drops seladelpar
Novartis takes $80M punt on early-stage NASH drug from Pliant
Alnylam hopes for 2018 filing for RNAi liver disease drug
Mary Szela has quit to avoid a conflict of interest.
Novo Nordisk board member quits over NASH conflict of interest
Company needs to make acquisition to grow, admits CEO.
Can Gilead find another Pharmasset in 2017?